Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JRNL | ISIN: US5703721028 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
MARIZYME INC Chart 1 Jahr
5-Tage-Chart
MARIZYME INC 5-Tage-Chart

Aktuelle News zur MARIZYME Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.04.Qualigen Announced An Agreement With Marizyme To Commercialize DuraGraft1
16.04.Marizyme Inc.: Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft75JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics...
► Artikel lesen
01.04.MARIZYME, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405-
06.02.MARIZYME, INC. - 8-K, Current Report-
28.12.23MARIZYME, INC. - 8-K, Current Report1
21.11.23MARIZYME, INC. - 8-K, Current Report1
14.11.23MARIZYME, INC. - 10-Q, Quarterly Report-
23.10.23Marizyme, Inc.: Marizyme CEO Delivers Business Update299Marizyme, Inc. Marizyme CEO Delivers Business Update 23-Oct-2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Marizyme CEO Delivers...
► Artikel lesen
13.10.23InvestmentPitch Media Video Features Marizyme's CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device304VANCOUVER, BC / ACCESSWIRE / October 13, 2023 / Marizyme, Inc. (OTCQB:MRZM), a global multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies...
► Artikel lesen
06.10.23The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News740VANCOUVER, BC / ACCESSWIRE / October 6, 2023 / The Watchlist by The Market Herald has announced the release of new interviews with FPX Nickel, Pelangio Exploration, Nicola Mining, and Max Resource discussing...
► Artikel lesen
06.10.23Marizyme, Inc.: Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft385Marizyme, Inc. Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft 06-Oct-2023 / 15:00 CET/CEST The issuer is solely responsible for the content...
► Artikel lesen
10.05.23Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products453DJ Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products Marizyme, Inc. Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1